8 active not recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 8 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Urogenital Abnormalities: new trials by email Literature Review of Urogenital Abnormalities trials Research Report on Urogenital Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome BAY 3401016, Placebo - Alport Syndrome | Phase 2 | Active not recruiting | Bayer | 60 | 2025-11-19 | 2026-10-29 |
| Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old Crinecerfont - Congenital Adrenal Hyperplasia | Phase 2 | Active not recruiting | Neurocrine Switzerland GmbH | 7 | 2025-09-30 | 2026-08-28 |
| Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo - Hypothalamic Obesity, Hypothalamic Tumor | Phase 2 | Active not recruiting | Seattle Children's Hospital | 24 | 2025-03-01 | 2026-10-16 |
| A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718 - Hypothalamic Obesity, Prader-Willi Syndrome | Phase 1 / Phase 2 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 111 | 2024-03-05 | 2026-10-09 |
| Metyrapone for Mild Autonomous Cortisol Secretion (MACS) Metyrapone - Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS) | Phase 2 | Active not recruiting | Mayo Clinic | 30 | 2023-12-19 | 2026-09-25 |
| A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome Lonapegsomatropin, Somatropin - Turner Syndrome | Phase 2 | Active not recruiting | Ascendis Pharma Endocrinology Division A/S | 48 | 2023-02-15 | 2026-05-13 |
| A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) AAV BBP-631 - Congenital Adrenal Hyperplasia | Phase 1 / Phase 2 | Active not recruiting | Adrenas Therapeutics Inc | 8 | 2021-07-01 | 2025-12-23 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
Adrenal Hyperplasia, Congenital (3) · Nephritis, Hereditary (2) · Sexual Infantilism (2) · ACTH Syndrome, Ectopic (1) · Craniopharyngioma (1) · Cushing Syndrome (1) · Diabetic Nephropathies (1) · Glomerulonephritis, IGA (1) · Glomerulosclerosis, Focal Segmental (1) · Hypothalamic Neoplasms (1) · Obesity (1) · Prader-Willi Syndrome (1) · Turner Syndrome (1)
Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Male Urogenital Diseases (8) · Urogenital Diseases (8) · Endocrine System Diseases (7) · Disorders of Sex Development (6) · Gonadal Disorders (6) · Genetic Diseases, Inborn (5) · Nutritional and Metabolic Diseases (4) · Adrenal Gland Diseases (3) · Adrenogenital Syndrome (3) · Gonadal Dysgenesis (3)
Atrasentan (1) · Human Growth Hormone (1) · Metyrapone (1) · Phentermine (1) · Qsymia (1) · crinecerfont (1) · lonapegsomatropin (1)
Adrenas Therapeutics Inc (1) · Ascendis Pharma Endocrinology Division A/S (1) · Bayer (1) · Mayo Clinic (1) · Neurocrine Switzerland GmbH (1) · Novartis Pharmaceuticals (1) · Rhythm Pharmaceuticals, Inc. (1) · Seattle Children's Hospital (1)
United States (7) · Germany (2) · Italy (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Canada (1) · China (1) · Czechia (1) · France (1) · India (1) · Japan (1) · Poland (1)
Christian L Roth, MD (1) · David Meeker (1) · Irina Bancos, MD (1) · Shana E McCormack, MD (1)